OCON Therapeutics Secures $10M in funding to Revolutionize Women’s Health with Advanced Drug Delivery Solutions
OCON Therapeutics announces FDA acceptance of IND Application for its flagship product IUB® Ballerine® and distribution agreements for Canada and Mexico boosting sales by $9.3 million
OCON Therapeutics has signed an exclusive licensing agreement with BioGenuine to market its products in China and Southeast Asian countries
OCON Therapeutics Awarded as Technology Pioneer by the World Economic Forum
OCON’s Pioneering IUB® Ballerine® Femtech Applauded by Frost & Sullivan
Femtech startup OCON Therapeutics announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB® SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)
OCON CEO Keren Leshem is featured on Forbes as one of the three women shaping the world of women’s health
FemTech startup OCON Therapeutics completes funding round and appoints Dr. Anula Jayasuriya to Chairwoman
FemTech startup OCON Therapeutics completes funding round and appoints Dr. Anula Jayasuriya to Chairwoman
Rhia Ventures Invests in OCON Healthcare’s Ballerine®, the first ever 3D spherical copper intrauterine contraceptive with a superior safety profile, a breakthrough in women’s hormone-free birth control options
